Guillain-Barré Syndrome Delayed Diagnosis: What Attorneys Need to Know About Neuromuscular Malpractice

Guillain-Barré syndrome (GBS) is a rapid-onset autoimmune neuropathy that can progress from mild limb weakness to complete paralysis and life-threatening respiratory failure within days. For attorneys evaluating potential malpractice cases, the central liability question is almost always one of recognition — whether the treating provider identified the progressive neurological pattern early enough to initiate monitoring, diagnostic workup, and evidence-based treatment before the patient deteriorated to respiratory failure or irreversible axonal injury. These cases carry significant damages because outcomes diverge sharply depending on whether the condition was identified and managed within the appropriate clinical window.

Understanding GBS and Why Timing Matters

GBS is an acute immune-mediated polyneuropathy, most often triggered by an antecedent infection — most commonly *Campylobacter jejuni* gastroenteritis, cytomegalovirus, Epstein-Barr virus, or, as documented in the post-pandemic era, SARS-CoV-2. The clinical hallmark is symmetrical ascending weakness beginning in the legs, typically accompanied by loss of deep tendon reflexes (areflexia) — a combination that, in a patient with a recent respiratory or gastrointestinal illness, should raise GBS to the top of the differential without delay.

In approximately 25 to 30 percent of GBS patients, weakness progresses to involve the respiratory muscles, diaphragm, and oropharynx, creating a risk of life-threatening respiratory failure and aspiration. Among patients who are not closely monitored, respiratory failure can develop insidiously: bedside examination underestimates pulmonary reserve, and a patient who appears to be breathing comfortably can decompensate acutely. The standard of care requires serial monitoring of forced vital capacity (FVC) and maximum inspiratory pressure (NIF) in hospitalized GBS patients — not reliance on oxygen saturation alone, which desaturates late in the course of neuromuscular respiratory failure.

Where Diagnostic Failures Occur

GBS misdiagnosis follows several recognizable patterns that a qualified neuromuscular expert identifies during case review.

Misattribution of back pain and leg weakness to musculoskeletal disease. In the earliest stages, GBS patients often complain of back pain and paresthesias in the legs before frank weakness becomes apparent. Providers in primary care and emergency settings who anchor on "sciatica" or "lumbar radiculopathy" without examining deep tendon reflexes systematically, and without recognizing the symmetrical pattern of involvement, delay the correct diagnosis by days or weeks. When an early visit documents leg weakness, decreased reflexes, and a recent gastrointestinal illness — and the patient is sent home with a musculoskeletal diagnosis — that record becomes the focal point of expert analysis.

Misdiagnosis as functional neurological disorder. GBS can produce symptoms that, to clinicians unfamiliar with neuromuscular disease, superficially resemble conversion disorder or functional neurological symptom disorder — particularly in younger patients with rapid-onset weakness and normal or borderline initial imaging. The critical difference is on neurological examination: GBS produces objective areflexia and verifiable weakness on muscle strength testing. Attributing objective exam findings to a functional etiology without appropriate neuromuscular workup is a deviation from the standard of care.

Delayed or absent lumbar puncture. The classic cerebrospinal fluid finding in GBS — elevated protein with a normal or near-normal white cell count (albuminocytologic dissociation) — develops within the first one to two weeks of symptom onset and is present in the majority of patients. The standard of care for a patient with progressive limb weakness and areflexia includes lumbar puncture to support or refute the diagnosis. Failure to perform LP — or performance of LP without appropriate interpretation of the results — is a common deviation in delayed-diagnosis GBS cases.

Failure to obtain nerve conduction studies. Electrodiagnostic testing — nerve conduction studies (NCS) and electromyography (EMG) — is the gold standard for confirming GBS and characterizing the subtype. The most common form in Western countries, acute inflammatory demyelinating polyneuropathy (AIDP), produces characteristic slowing of nerve conduction velocities, prolonged distal latencies, and conduction block. Axonal subtypes (AMAN and AMSAN) produce different electrodiagnostic patterns and carry a substantially worse prognosis. A clinically active neuromuscular specialist is positioned to testify on whether electrodiagnostic testing was obtained, whether it was performed and interpreted correctly, and whether the results were communicated urgently when they confirmed the diagnosis.

Standard of Care for GBS Diagnosis and Treatment

### Lumbar Puncture and Electrodiagnostics

When GBS is clinically suspected based on ascending weakness, areflexia, and a compatible history, the standard of care requires prompt LP and neurology consultation for NCS/EMG. Awaiting LP results before initiating treatment in a rapidly progressing patient is not required; clinical severity at presentation is itself an indication for early treatment in patients with significant weakness. The Brighton Collaboration case definition, widely used in clinical and research settings, stratifies diagnostic certainty and reinforces the centrality of LP and electrodiagnostics in GBS evaluation.

### Respiratory Monitoring

Every hospitalized GBS patient requires serial measurement of FVC and NIF at regular intervals — typically every four to six hours in the acute phase — to detect impending respiratory failure before oxygen desaturation occurs. Current neurology practice guidelines identify the "20-30-40" thresholds (FVC below 20 mL/kg, NIF less negative than −30 cm H₂O, maximum expiratory pressure below 40 cm H₂O) as indications for ICU transfer and preparation for intubation. Failure to monitor respiratory function with serial spirometry — relying instead on pulse oximetry or respiratory rate alone — is a recognized deviation from the standard of care when GBS is confirmed or clinically suspected.

### IVIG or Therapeutic Plasma Exchange

For patients with significant weakness or rapid progression, the two evidence-based treatments for GBS are intravenous immunoglobulin (IVIG) at 0.4 g/kg/day for five days and therapeutic plasma exchange (plasmapheresis). Both are supported by randomized controlled trial evidence and Cochrane systematic reviews demonstrating equivalent efficacy. Corticosteroids are not effective as monotherapy for GBS and are not recommended by current American Academy of Neurology (AAN) guidelines — their administration does not substitute for IVIG or plasma exchange, and cases have arisen in which steroid therapy was used in place of or as a delay to evidence-based treatment.

Treatment delays that allow progression to mechanical ventilation or axonal degeneration carry direct causation significance. Axonal GBS subtypes (AMAN, AMSAN) — which may be favored by specific precipitating infections, particularly *Campylobacter* — carry a substantially worse long-term prognosis than demyelinating AIDP. When delayed diagnosis prevents timely electrodiagnostic characterization and treatment initiation, expert analysis links the treatment delay to the documented trajectory of decline.

Liability Patterns Attorneys Encounter

### Emergency Department Failures

The emergency department is a common first point of contact for patients presenting with acute leg weakness and sensory changes. The liability pattern typically involves a patient whose neurological examination documented diminished or absent reflexes — findings that are recorded in the nursing or physician note — but who was assessed for orthopedic or musculoskeletal pathology without neurology consultation, LP, or electrodiagnostic workup. When the patient returns days later with respiratory compromise or quadriplegia, the initial ED record demonstrates that the clinical picture was present and unrecognized.

### Inpatient Monitoring Failures

Admitted GBS patients who are not placed on respiratory monitoring protocols and deteriorate without warning represent a distinct and serious liability category. When nursing flowsheets document declining functional status — inability to lift arms above the bed, difficulty swallowing, accessory muscle use — without corresponding escalation of respiratory monitoring or ICU transfer, the failure to act on documented deterioration becomes the core of the expert's breach analysis.

### Primary Care Diagnostic Delay

Patients who present to primary care or urgent care with progressive leg weakness over multiple visits face particular risk when providers interpret the evolution as musculoskeletal or functional without systematic neurological assessment. A pattern of multiple visits with progressive, documented weakness, absent reflexes, and no neurology referral establishes both breach and the opportunity for earlier treatment that was lost.

Daubert and Admissibility Considerations

GBS malpractice cases require expert testimony in neurology or, preferably, neuromuscular medicine — the subspecialty with direct expertise in electrodiagnostic testing, peripheral nerve disease, and the management of neuromuscular emergencies. A general neurologist who does not perform nerve conduction studies personally, or who does not manage ventilated GBS patients in current practice, faces admissibility challenges when testimony turns on electrodiagnostic interpretation, respiratory monitoring standards, or treatment timing.

The most defensible GBS opinions are provided by fellowship-trained, board-certified neuromuscular specialists with active clinical and electrodiagnostic practices. The methodology for GBS causation analysis — reconstructing the clinical timeline against accepted diagnostic and treatment benchmarks, and opining on whether earlier treatment would have prevented progression to respiratory failure or long-term disability — must be grounded in published AAN practice guidelines and peer-reviewed trial data, not in eminence alone.

How ApexMedLaw Supports Guillain-Barré Syndrome Malpractice Cases

GBS litigation requires expert witnesses who actively manage neuromuscular emergencies, perform and interpret nerve conduction studies, and understand respiratory monitoring protocols from direct clinical practice. Our neuromuscular medicine division features fellowship-trained, board-certified neuromuscular specialists with high-volume electrodiagnostic and active clinical practice across inpatient and outpatient neuromuscular care.

We provide:

- Rapid case screening with review of the clinical presentation, examination findings, and diagnostic workup timeline

- Expert analysis of whether LP, NCS/EMG, and neurology consultation were obtained in a timely manner consistent with the standard of care

- Assessment of respiratory monitoring practices against published 20-30-40 thresholds and neuromuscular respiratory failure standards

- Evaluation of whether IVIG or plasma exchange was initiated at the appropriate stage of the patient's clinical course

- Causation analysis tying any treatment delay to documented neurological progression — including preventable respiratory failure, prolonged ventilator dependence, or long-term disability from axonal subtype injury

- Deposition and trial-ready testimony from board-certified neuromuscular specialists with active electrodiagnostic practice

Whether the case involves a missed diagnosis in the emergency department, delayed neurology consultation allowing respiratory decompensation, or substitution of ineffective steroid therapy for evidence-based treatment, our experts evaluate the clinical record with the specificity this medicine demands.

Contact ApexMedLaw to discuss your Guillain-Barré syndrome malpractice case.

This post is for informational purposes and does not constitute legal advice. Standards vary by jurisdiction.